Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by Felcoon Jun 04, 2017 11:36pm
436 Views
Post# 26323078

RE:RE:RE:RE:RE:RE:RE:RE:RE:take-out , soon at these prices

RE:RE:RE:RE:RE:RE:RE:RE:RE:take-out , soon at these prices A few points regarding your comparisons.  Certainly as a matter of scale Tesla is multiple times PLI's size, but that doesn't really change the underlying dynamic, they are both losing money.  I certainly agree with less than a years worth of cash to draw on, it's a heavy drag on the share price.  I've commented on this previously, questioning some of the management's decisions with regards to implimentation and timing.  I would question your characterization of PLI's Reputation of quality as 'Not yet'.  I would suggest GSK would disagree with you.  Remember, it was GSK, when PLI was running of fumes and in real danger of folding, that still went to PLI based on the quality their platform technology provided.  As a service provider to other pharmaceutical companies, I don't think PLI is held in other than the highest regards.  I presume your reference was more to PLI as the burgeoning pharma company?

Thanks for taking the time to provide a thoughtful rebuttal.To close the conversation, take your comparibles for PLI and Tesla and overlay Tesla against GM and Telsa doesn't quite look the shiny jewel the market indicates it is.  GM would best them on most every count, but Mr. market views Tesla as something more than what it is, a car manufacturing company.  Even if it could meet its goal of a 500,000 unit output, it would only represent 5% of GM's present capacity.  How easily could they scale to 1,000,000 units? 210,000 units sold and it's worth more by market cap than GM. It's the  obsurdtity of the valuation that I used to illustrate my point of not underestimating where the market cap could go on PLI.  

Like yourself, I'd be very happy with $9.00 and I'm comforted by the fact that in the eyes of more than a handful of analysts, it's a distinct possibility.

Good luck,
Felco
Bullboard Posts